{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T03:20:00Z","timestamp":1765423200383},"reference-count":101,"publisher":"Informa UK Limited","issue":"5","funder":[{"name":"funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2021,5,4]]},"DOI":"10.1080\/14712598.2021.1857720","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T08:44:38Z","timestamp":1606725878000},"page":"649-659","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Cell therapy for cytomegalovirus infection"],"prefix":"10.1080","volume":"21","author":[{"given":"Lorna","family":"Neill","sequence":"first","affiliation":[{"name":"Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Peggs","sequence":"additional","affiliation":[{"name":"UCL Cancer Institute, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,12,21]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112666"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.5.1373.1373"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.5.1672.bloodjournal8251672"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.2.467"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11912"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050882"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2010.11.011"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3263"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-203307"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3616"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.7.2240"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0993"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00239-4"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1086\/315092"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.2004"},{"key":"cit0016","first-page":"1","volume":"42","author":"Gerna G","year":"2019","journal-title":"New Microbiol"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01910-07"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2008.01084.x"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2010.00504.x"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.02.009"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.3.638-640.1998"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.7.2815.2815"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit475"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-688432"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08988.x"},{"key":"cit0026","first-page":"51","volume":"48","author":"Foulongne V","year":"2004","journal-title":"Acta Virol"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00633-06"},{"key":"cit0028","unstructured":"National Institute for Health and Care Excellence [Internet]. Letermovir for preventing cytomegalovirus disease after a stem cell transplant NICE [Internet]. NICE; 2019 [cited 2020 Jun 6]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta591\/chapter\/1-Recommendations."},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706640"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.05265-11"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.388"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-3-199302010-00003"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2502"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/166.3.473"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.4.1159"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303688"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.09.038"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.04.028"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2018.05.014"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128766"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714656"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70024-X"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2006.07.010"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.06.009"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1689.1689"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409083311017"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1126\/science.1352912"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199510193331603"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.11.3916"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.4.994"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14634-X"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1086\/648422"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2007.02.004"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-448977"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1775"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20040613"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis625"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1038\/nm0602-631"},{"key":"cit0059","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.4049\/jimmunol.163.8.4342","volume":"163","author":"Whelan JA","year":"1999","journal-title":"J Immunol"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02940.x"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.16"},{"key":"cit0062","first-page":"796","volume":"138","author":"Khanna R","year":"2013","journal-title":"Indian J Med Res"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-262089"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq042"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-371971"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-486324"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.17"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.184.184"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.08.024"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017010223"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000371"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.0655"},{"key":"cit0073","unstructured":"Allo V. Phase 3 multicenter, double-blind, placebo-controlled trial of viralym-M (ALVR105) for the treatment of patients with virus-associated hemorrhagic cystitis after allogeneic hematopoietic cell transplant (HCT) [Internet]. clinicaltrials.gov; 2020 [cited 2020 Jul 16]. Report No.: NCT04390113. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04390113."},{"key":"cit0074","unstructured":"Memorial Sloan Kettering Cancer Center. A phase II trial of third party donor derived CMVpp65 specific T-cells for the treatment of CMV Infection or persistent CMV viremia after allogeneic hematopoietic stem cell transplantation [Internet]. clinicaltrials.gov; 2020 [cited 2020 Jul 16]. Report No.: study\/NCT02136797. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02136797."},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-213256"},{"key":"cit0076","first-page":"e3627","author":"Hanley PJ","year":"2012","journal-title":"J Vis Exp"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2017.02.001"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000201"},{"key":"cit0079","unstructured":"Bollard C. Adoptive cord blood immunotherapy for EBV, CMV, BKV and adenovirus reactivation\/infection or prophylaxis [Internet]. clinicaltrials.gov; 2020. [cited 2020 Jul 17]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT03594981."},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa2546"},{"key":"cit0081","unstructured":"Bollard C. Allogeneic multivirus - directed cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (hexon and penton) [Internet]. clinicaltrials.gov; 2020 [cited 2020 Jul 16]. Report No.: study\/NCT01945814. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01945814."},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902233"},{"key":"cit0083","unstructured":"University College, London. CMV tcr gene therapy: a phase I safety, toxicity and feasibility study of adoptive immunotherapy with CMV TCR-transduced donor-derived T cells for recipients of allogeneic haematopoietic stem cell transplantation [Internet]. clinicaltrials.gov; 2018 [cited 2020 Jun 11]. Report No.: NCT02988258. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02988258."},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1394-x"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2019.149"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-242263"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-506741"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1232"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-664755"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12475"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1086\/342385"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02672.x"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2015.5"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2015.12.031"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00289-6"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1086\/338624"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.03.020"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2019.001"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4016-1"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.130"},{"key":"cit0101","unstructured":"Klinikum der Universit\u00e4t M\u00fcnchen. Treatment of chemo-refractory viral infections after allogenic stem cell transplantation with multispecific T cells against CMV, EBV and AdV: a phase III, prospective, multicentre clinical trial [Internet]. clinicaltrialstegister.eu; 2018 [cited 2020 Jun 17]. Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2018-000853-29\/DE"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2021.1857720","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T06:49:11Z","timestamp":1697266151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2021.1857720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,21]]},"references-count":101,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5,4]]}},"alternative-id":["10.1080\/14712598.2021.1857720"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2021.1857720","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-08-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}